Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

With private asset ETFs still awaiting regulatory approval, opportunistic issuers are continuing to crank out products that ...

As private equity continues to shape the Irish M&A landscape, experts predict strong activity in the coming years, fueled by ...

Companies, mainly those in the tech sector, are tapping into a rebound in investor sentiment fueled by hopes of Beijing's ...

Private equity, the harbinger of all bad things, is getting its greasy little hands on Willow Springs Raceway in Rosamond, ...

Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note.

California state Sen. Christopher Cabaldon has introduced a bill that would bar private equity and hedge funds invested in a ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

The California legislature recently introduced legislation, SB 351, that would impact private equity or hedge funds managing ...